When looking at all pTRC, however, their proportion was higher in responding relative to non-responding tumors (p = 0.047; Fig. 6A) and was negatively correlated with percent residual tumor (Fig. 6B; R = −0.55, p = 0.035), compatible with the notion that MANA-specific cells are important drivers of anti-tumor immunity during PD-1 blockade. The gene discussed is PDCD1; the disease is neoplasm.